In this article, we deep dive into the 5 stocks that defied the lackluster performance of the broader market. For a deeper discussion and an extended list, please see 9 Stocks Winning by Double Digits.

5. Nurix Therapeutics Inc. (NASDAQ:NRIX)

Nurix Therapeutics extended its gains to an 8th straight session on Thursday, touching a new 52-week high, as investors resumed buying positions following an earlier partnership with Roche for the co-development of a blood cancer treatment.

In intra-day trading, the stock climbed to a record high of $23.09 before trimming gains to end the day just up by 16.37 percent at $22.46 apiece.

In a statement, Nurix Therapeutics Inc. (NASDAQ:NRIX) said that it joined forces with Roche to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton’s tyrosine kinase (BTK).

According to the two parties, the collaboration encompasses a comprehensive clinical development plan spanning malignant hematology, immunology and neurology intended to explore the full clinical potential of BTK degradation across diverse patient populations. In addition to the Phase 2 and Phase 3 trials in chronic lymphocytic leukemia, the collaboration plans to pursue multiple label-enabling studies across a range of malignant hematology indications as monotherapy and in combination regimens,  and expand development into immune-mediated diseases, including Phase 2 trials in MS and CSU.

“Partnering with Roche, a world leader in the treatment of B-cell malignancies, positions Nurix to fully realize the potential of bexobrutideg across multiple indications in oncology, immunology, and neurology,” Nurix Therapeutics Inc. (NASDAQ:NRIX) President and CEO Arthur Sands said.

As part of the agreement, Nurix Therapeutics Inc. (NASDAQ:NRIX) is set to receive $700 million in upfront cash payments and is eligible to receive up to $2.3 billion upon milestone achievement.

4. BlackBerry Ltd. (NYSE:BB)

BlackBerry saw its share prices jump by 19.95 percent on Thursday to close at $10.34 apiece, after more than quadrupling its net income in the first quarter of fiscal year 2027.

In an updated report, BlackBerry Ltd. (NYSE:BB) said that it raked in $8.5 million in net income during the period, marking a growth of 347 percent from the $1.9 million in the same period last year.

Revenues increased by 25.6 percent to $152.9 million from $121.7 million, thanks to a strong 26-percent revenue jump from its QNX business at $72.3 million, and a 24-percent increase in revenues from secure communications.

The actual revenues exceeded its $132 million to $140 million guidance for the quarter.

“Our first quarter results demonstrate continued momentum following our transformation, as we advance our strategy to drive profitable growth. We exceeded expectations for revenue, profitability, and cash generation through solid performance by our world-class QNX and Secure Communications teams,” BlackBerry Ltd. (NYSE:BB) CEO John Giamatteo said.

“We are particularly encouraged by the multi-year growth opportunities ahead in software-defined vehicles, including significant content expansion with the Alloy Kore platform, as well as broad opportunities in the general embedded market, especially physical AI. We believe these opportunities significantly enhance QNX’s long-term potential,” he added.

Looking ahead, BlackBerry Ltd. (NYSE:BB) raised its growth outlook for the full fiscal year 2027 to a range of $594 million to $621 million, versus $584 million to $611 million previously.

In the second quarter alone, revenues are targeted to be in the range of $137 million to $148 million.

3. Bio-Techne Corp. (NASDAQ:TECH)

Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors gobbled up shares following news that it is merging with pharmaceutical giant Merck for $11.3 billion.

In a statement, Bio-Techne Corp. (NASDAQ:TECH) said that it officially entered into a definitive agreement with Merck for the all-cash sale of its shares at a price of $73 apiece. The price marked a 24-percent upside potential from its closing price of $58.88 on Wednesday, prior to the announcement.

“Following a thorough review, Bio-Techne’s Board of Directors determined that this transaction represents an excellent opportunity for Bio-Techne and delivers substantial, near-term cash value to shareholders. We are confident that, as part of Merck KGaA, Darmstadt, Germany, Bio-Techne will be well positioned to leverage its strong foundation and expand its impact across life sciences,” Bio-Techne Corp. (NASDAQ:TECH) Chairman Robert Baumgartner said.

Both parties target to complete the transaction by late 2026 or early 2027, subject to satisfaction of customary closing conditions, including the receipt of required regulatory approvals and approval by Bio-Techne Corp. (NASDAQ:TECH) shareholders.

2. Sandisk Corp. (NASDAQ:SNDK)

Sandisk soared to an all-time high anew on Thursday, as investors continued to load up on its shares after Micron Technology’s stellar earnings performance that validated the ongoing strong demand for the memory market.

In intra-day trading, Sandisk Corp. (NASDAQ:SNDK) climbed to a fresh all-time high of $2,348 before paring gains to end the session just up by 21.53 percent at $2,335 apiece.

In its earnings release, Micron said that its record earnings performance and even stronger outlook for the fourth quarter of fiscal year 2026 “reflect the strategic value of memory in the AI era.”

Investment firm Citigroup raised its price target for Sandisk Corp. (NASDAQ:SNDK) by 23 percent to $2,500 from $2,025 previously, following Micron’s comments, while maintaining its buy recommendation.

It said that the coverage was amid an improving outlook for the NAND market following Micron’s better-than-expected results, noting that demand for NAND memory is exceeding supply, with tightness anticipated further beyond 2027.

“We remain constructive on favorable NAND supply/demand fundamentals on durable AI-led datacenter demand (KV cache offloading to more cost-effective SSDs),” Citigroup said.

1. DPC Holdings Limited (NYSE:DPC)

DPC Holdings soared by 42.06 percent in its first trading day amid a continued strong investor appetite for the aerospace and defense market.

During the session, DPC Holdings Limited (NYSE:DPC) opened at $44, immediately clocking a 33-percent jump from its initial public offering (IPO)price of $33. It hit as high as $47.09, marking a growth of 42.7 percent.

DPC Holdings Limited (NYSE:DPC) was able to raise $919.3 million from the successful sale of more than 27.8 million ordinary shares, with the potential to raise the total to $1.06 billion if the underwriters exercise their 30-day option to purchase over 27.8 million shares at the IPO price.

The company said that it intends to use its net proceeds from the offer to repay outstanding indebtedness, including a payment-in-kind to one of its shareholders. The balance will be used for general corporate purposes, including working capital, future growth projects, and amounts due under its cash-based management incentive plan.

DPC Holdings Limited (NYSE:DPC) is a portfolio company of the private equity and credit investment group, JF. Lehman & Company, LLC (JFLCO). It is engaged in the production of complex, highly engineered precision cast components and nickel and cobalt-based superalloys primarily serving the aerospace and IGT end markets.

“Doncaster’s successful initial public offering represents the next chapter of the company’s long-term focus on operational excellence and customer-centric growth. We are thrilled to have contributed to Doncaster’s evolution and look forward to its next chapter as a public company,” said DPC Holdings Limited (NYSE:DPC) Director Alex Harman.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.